Bioequivalence Study of AG2202
NCT06549504 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34
Last updated 2024-08-14
Summary
The objective of this study is to evaluate the human bioequivalence of AG2202T and AG2202R.
Conditions
- Bioequivalence Study
Interventions
- DRUG
-
AG2202T
AG2202T Single-dose
- DRUG
-
AG2202R
AG2202R Single-dose
Sponsors & Collaborators
-
Ahn-Gook Pharmaceuticals Co.,Ltd
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-08-31
- Primary Completion
- 2024-09-30
- Completion
- 2024-09-30
More Related Trials
-
A Bioequivalence Study of CT-L02 Compared to Co-administration (CTL0201 and CTL0202) in Healthy Volunteers
NCT07128654 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study Between YHP2406 and YHR2501 in Healthy Subjects
NCT07265167 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study Between "DA-5215 Tab" and "DA-5215-R Tab"
NCT05376085 ·Status: UNKNOWN ·Phase: PHASE1
-
Bioequivalence Study of Digoxin Tablet in Healthy Subjects
NCT06546215 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Eldecalcitol Soft Capsule in Healthy Chinese Subjects
NCT05406050 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence of Two Formulations of Parecoxib in Healthy Volunteers Under Fasting Conditions
NCT06600282 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452
NCT05722262 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Apixaban Tablets in Healthy Chinese Subjects
NCT05841446 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects
NCT06678542 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Tacrolimus in Healthy Volunteers
NCT04725682 ·Status: COMPLETED ·Phase: PHASE1
-
A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers
NCT02074553 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects
NCT06168929 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants
NCT02230046 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study Between UI009 and UIC202005 in Healthy Subjects
NCT07110740 ·Status: COMPLETED ·Phase: PHASE1
-
Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg
NCT06233266 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012
NCT01420458 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of CJ-30060 in Healthy Male Volunteers
NCT03639493 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Etoricoxib in Healthy Adult Subjects Under Fasting Condition
NCT05532280 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study Between "DA-5209 Tab" and "Lixiana Tab"
NCT04671316 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of CJ-30060 in Healthy Volunteers
NCT03757390 ·Status: UNKNOWN ·Phase: PHASE1
-
Bioequivalence Study Between YHP1906 Tab. 5 mg and YHR1902 Tab. 5 mg
NCT04316065 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284
NCT06884098 ·Status: RECRUITING ·Phase: PHASE1
-
Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects
NCT06107205 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fed Condition
NCT04445922 ·Status: UNKNOWN ·Phase: PHASE1
-
Bioequivalence Study of Azilsartan Tablets in Chinese Healthy Volunteers
NCT03652792 ·Status: COMPLETED ·Phase: PHASE1